Investigational drug · Phase 2
SKB118
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Squamous Non-Small Cell Lung Cancer, Advanced Solid Tumors, NSCLC.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "SKB118"
First trial start
2026
Jun 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SKB118", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Squamous Non-Small Cell Lung Cancer
- Advanced Solid Tumors
- NSCLC
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SKB118" as an intervention, largest first.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT07586943 · 530 participants (planned) · Start Jun 1, 2026 · Primary completion Dec 2029
Drug: SKB118 Injection; SKB118+SKB264 · For: Advanced Solid Tumors
Sites: Shanghai, China
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT07697586 · 206 participants (planned) · Start Aug 7, 2026 · Primary completion Aug 2028
Drug: SKB264+SKB118 · For: NSCLC
Sites: Jilin City, China; Shanghai, China
- A Phase II Study of SKB264 + SKB118 in Nsq-NSCLC After EGFR-TKI FailureNot yet recruiting
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
NCT07854509 · 110 participants (planned) · Start Oct 15, 2026 · Primary completion Dec 30, 2027
Drug: SKB264+SKB118 · For: Non-Squamous Non-Small Cell Lung Cancer
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non-Squamous Non-Small Cell Lung Cancer
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- Telisotuzumab AdizutecanABBV-400Phase 316 trials
AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- AumolertinibSHR-A2009, HS-10296Phase 37 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer, Advanced Solid Tumors
- EU-sourced KeytrudaPhase 32 trials
Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer
- US-sourced KeytrudaPhase 32 trials
Shanghai Henlius Biotech · Non-Squamous Non-Small Cell Lung Cancer, Non Squamous Non Small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.